Results 71 to 80 of about 6,049 (169)
A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout
MicrobiologyOpen, Volume 15, Issue 5, October 2026.Schematic summary of the therapeutic mechanisms and evaluation of the post–NGP strain M. jalaludinii PMC73 for gout. PMC73 demonstrated uric acid–lowering efficacy through purine catabolism and hypoxanthine utilization, along with intracellular uric acid reduction in macrophages.
Mohammed Solayman Hossain +13 more
wiley +1 more source
Management of hyperuricemia in gout: focus on febuxostat
, 2010 Mattheus K Reinders1, Tim L Th A Jansen21Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands; 2Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, The NetherlandsAbstract: Gout is the most common inflammatory arthritis in an ...
Tim L Th A Jansen, Mattheus K Reinders
core
Experience with febuxostat in a patient with severe disabling gout [PDF]
, 2017 Gout is a chronic disease that frequently leads to disability if urate-lowering therapy is inefficient. The paper presents the positive experience with febuxostat, a novel non-purine xanthine oxidase inhibitor, in a young patient with disabling chronic ...
R. U. Shayakhmetova, M. S. Eliseev
core +1 more source
ACR Open Rheumatology, Volume 8, Issue 9, September 2026.Objective To evaluate the management practices of rheumatologists and nephrologists in treating patients with uncontrolled gout. Methods US board‐certified rheumatologists and nephrologists treating patients with uncontrolled gout participated in a web‐based, retrospective medical record audit study, sharing their perceptions of uncontrolled gout ...
Kenneth Saag +7 more
wiley +1 more source
Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
, 2019 Background. Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a ...
Cuenca, John A +5 more
core +1 more source
Arthritis Research & Therapy, 2019 Background This study investigates the association between exposure to urate-lowering drugs (ULDs) and progression and recovery from chronic kidney disease (CKD). Methods We identified 5860 incident gout patients at Chang Gung Memorial Hospital from 2012
Ting-Ting Chung +9 more
doaj +1 more source
Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
, 2010 Lada Beara-Lasic1,3, Michael H Pillinger2,3, David S Goldfarb1,31Divisions of Nephrology and 2Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, USA; 3Department of Medicine, New York Harbor VA Health Care System, New York ...
David S Goldfarb +2 more
core
Desensitization to febuxostat: report of two cases.
, 2015 Febuxostat has been recently introduced in the market as an alternative urate-lowering drug. Its allergenic profile has not been fully outlined and the clinical management of hypersensitivity reactions is not standardized.
Tosoni C. +6 more
core +1 more source
, 2014 Tadashi Sofue,1 Masashi Inui,2 Taiga Hara,1 Yoko Nishijima,1 Kumiko Moriwaki,1 Yushi Hayashida,3 Nobufumi Ueda,3 Akira Nishiyama,4 Yoshiyuki Kakehi,3 Masakazu Kohno1 1Division of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular ...
Inui M +9 more
core
Febuxostat for the treatment of hyperuricaemia in gout
, 2018 Introduction: Febuxostat is a potent non-purine selective xanthine oxidase inhibitor approved by the FDA in 2009 for management of hyperuricemia in people with gout.Areas covered: The authors summarize the pre-clinical studies and pivotal randomized ...
Dalbeth, Nicola +2 more
core +1 more source